Based on the PolyPid stock forecast from 4 analysts, the average analyst target price for PolyPid is USD 12.50 over the next 12 months. PolyPid’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of PolyPid is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, PolyPid’s stock price was USD 3.22. PolyPid’s stock price has changed by +23.37% over the past week, -7.74% over the past month and -17.99% over the last year.
No recent analyst target price found for PolyPid
No recent average analyst rating found for PolyPid
Company Overview PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. Read Less
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX1...Read More
Frequently Asked Questions About PolyPid (PYPD) Stock
Based on ratings from 4 analysts PolyPid's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 5 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on PYPD's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for PYPD is USD 12.50 over the next 12 months. The maximum analyst target price is USD 14 while the minimum anlayst target price is USD 10.
Unfortunately we do not have enough data on PYPD's stock to indicate if its overvalued.
The last closing price of PYPD's stock was USD 3.22.
The most recent market capitalization for PYPD is USD 0.02B.
Based on targets from 4 analysts, the average taret price for PYPD is projected at USD 12.50 over the next 12 months.
This means that PYPD's stock price may go up by +288.20% over the next 12 months.
We can't find any ETFs which contains PolyPid's stock.
As per our most recent records PolyPid has 59 Employees.
PolyPid's registered address is 18 Hasivim Street, Petah Tikva, Israel, 4959376.
You can get more information about it from PolyPid's website at https://www.polypid.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About PolyPid (PYPD) Stock
Based on ratings from 4 analysts PolyPid's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 5 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on PYPD's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for PYPD is USD 12.50 over the next 12 months. The maximum analyst target price is USD 14 while the minimum anlayst target price is USD 10.
Unfortunately we do not have enough data on PYPD's stock to indicate if its overvalued.
The last closing price of PYPD's stock was USD 3.22.
The most recent market capitalization for PYPD is USD 0.02B.
Based on targets from 4 analysts, the average taret price for PYPD is projected at USD 12.50 over the next 12 months.
This means that PYPD's stock price may go up by +288.20% over the next 12 months.
We can't find any ETFs which contains PolyPid's stock.
As per our most recent records PolyPid has 59 Employees.
PolyPid's registered address is 18 Hasivim Street, Petah Tikva, Israel, 4959376.
You can get more information about it from PolyPid's website at https://www.polypid.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PYPD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
